Search results
Found 13 matches for
The collective force of cancer research, outreach and care across the city of Oxford, translating discoveries into better care for cancer patients.
Dr Lennard Lee recognised as one of the world's 21 outstanding young physicians below the age of 40
19 October 2022
Dr Lennard Lee, academic clinical lecturer at the Department of Oncology was recognised as part of the InterAcademy Partnership Young Physician Leaders Programme 2022
Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine
20 July 2022
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.
Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination
24 May 2022
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
Strong immune responses in myeloma patients after two doses of COVID vaccine
29 November 2021
A study of 214 patients with myeloma finds that 93% of them produced T cells as well as antibodies to the SARS-CoV-2 spike protein after two doses of a COVID vaccine.
Fewer cases of children’s cancer picked up during COVID pandemic
12 November 2021
An Oxford study of cancer in children and young adults in England has found that fewer patients were diagnosed during the COVID-19 pandemic, but cancer diagnosis following admission to intensive care was higher.
Vaccinated patients who are immunosuppressed from chemotherapy identified as highest risk for hospitalisation and death
3 November 2021
Researchers from the University of Oxford have identified which vaccinated people are at greatest risk from severe Covid-19 leading to hospitalisation or death, from 14 days after the second dose of vaccination, when substantial immunity should be expected.
Reduced antibody response to COVID vaccination in myeloid blood cancers patients
17 June 2021
Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.
Prioritising COVID-19 research questions for the cancer population
6 April 2021
UK Coronavirus Cancer Monitoring Project (UKCCMP) lead Dr Lennard Lee talks to the NCRI about what clinician-patient collaboration and public involvement in research can do for cancer research and its outcomes
New Oxford technology assesses cancer patient vulnerability to COVID-19
23 February 2021
New research from Prof Julia Hippisley-Cox has resulted in thousands of cancer patients being given prioritised access to the COVID-19 vaccine.
Bowel cancer patients going undiagnosed due to COVID distruption
15 January 2021
A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.
Helping blood cancer patients in the COVID era
22 September 2020
The Oxford-led UK Coronavirus Cancer Monitoring Project was launched earlier this year to help clinicians better treat blood cancer patients in a safe way during the COVID-pandemic
The impact of COVID-19 on cancer patients
24 August 2020
A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has investigated which cancer patients may be more susceptible to the impacts of coronavirus
Oxford joins cancer coronavirus registry project
22 May 2020
Oncologists in Oxford join Leeds, Birmingham and more universities to help monitor COVID-19 positive cancer patients